Abstract:Chronic kidney disease (CKD) inevitably progresses to end-stage renal disease if intervention does not occur timely. However, there are limitations in predicting the progression of CKD by solely relying on changes in renal function. A biomarker with high sensitivity and specificity that can predict CKD progression early is required. We used the online Gene Expression Omnibus microarray dataset GSE45980 to identify differentially expressed genes (DEGs) in patients with progressive and stable CKD. We then performed functional enrichment and protein-protein interaction network analysis on DEGs and identified key genes. Finally, the expression patterns of key genes were verified using the GSE60860 dataset, and the receiver operating characteristic curve analysis was performed to clarify their predictive ability of progressive CKD. Ultimately, we verified the expression profiles of these hub genes in an in vitro renal interstitial fibrosis model by real-time PCR and western blot analysis. Differential expression analysis identified 50 upregulated genes and 47 downregulated genes. The results of the functional enrichment analysis revealed that upregulated DEGs were mainly enriched in immune response, inflammatory response, and NF-κB signaling pathways, whereas downregulated DEGs were mainly related to angiogenesis and the extracellular environment. Protein-protein interaction network and key gene analysis identified CCR7 as the most important gene. CCR7 mainly plays a role in immune response, and its only receptors, CCL19 and CCL21, have also been identified as DEGs. The receiver operating characteristic curve analysis of CCR7, CCL19, and CCL21 found that CCR7 and CCL19 present good disease prediction ability. CCR7 may be a stable biomarker for predicting CKD progression, and the CCR7-CCL19/CCL21 axis may be a therapeutic target for end-stage renal disease. However, further experiments are needed to explore the relationship between these genes and CKD.

CCL7 as a novel inflammatory mediator in cardiovascular disease, diabetes mellitus, and kidney disease

CCL7 Contributes to Angiotensin II-induced Abdominal Aortic Aneurysm by Promoting Macrophage Infiltration and Pro-Inflammatory Phenotype.

Inhibition of CCL7 improves endothelial dysfunction and vasculopathy in mouse models of diabetes mellitus

Crucial Biological Functions of CCL7 in Cancer

Multifaceted Roles of Chemokine C-X-C Motif Ligand 7 in Inflammatory Diseases and Cancer

CCL24/CCR3 Axis Plays a Central Role in Angiotensin II–induced Heart Failure by Stimulating M2 Macrophage Polarization and Fibroblast Activation

Role of the CCL2-CCR2 axis in cardiovascular disease: Pathogenesis and clinical implications

Role of CX3CL1 in Diseases

Relevance of the chemokine CXCL12/CXCR7 axis in cardiovascular disease

The Role of CXC Chemokines in Cardiovascular Diseases

CCL7 Chemokine Is a Marker but Not a Therapeutic Target of Acute Kidney Injury

Chemokines, chemokine receptors, and renal disease: from basic science to pathophysiologic and therapeutic studies

Role of Chemokine(c-C Motif) Ligand 5 Andits Receptor CCR5 in Diabetic Complication

CCL13 and human diseases

Bioinformatics analysis reveals CCR7 as a potential biomarker for predicting CKD progression

Role of Chemokine-Like Factor 1 As an Inflammatory Marker in Diseases

Contribution of Homeostatic Chemokines CCL19 and CCL21 and Their Receptor CCR7 to Coronary Artery Disease

CCL5/CCR5 axis in human diseases and related treatments

The role of CCL8 in immune regulation of diseases

The Roles of CCR9/CCL25 in Inflammation and Inflammation-Associated Diseases

C-C Motif Chemokine 2 Regulates Macrophage Polarization and Contributes to Myocardial Infarction Healing.